Drug Trial Radar · NCT00004266
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Mar 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Aug 1993
Primary completion
Jul 1999
Study completion Jul 1999
Sponsor
- Sponsor type
- NIH
- Collaborators
- Hennepin County Medical Center, Minneapolis
- First posted
- Oct 19, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
Conditions
- Diabetic Nephropathy
Interventions
LisinoprilDrug
NifedipineDrug
SimvastatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hennepin County Medical Center
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.